Targeting p53-mdm2 interaction by small-molecule inhibitors: learning from mdm2 inhibitors in clinical trials

HIGHLIGHTS

• who: Haohao Zhu from the (UNIVERSITY) have published the Article: Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials, in the Journal: (JOURNAL)
• what: The trans conformation of the two benzene rings of MI-888 is the main reason for the enhanced binding ability of MI-888 to the MDM2 protein.
• how: The preliminary results showed that the complete remission rate reached 25% and the median remission time was approximately 6.4 months which was related to the level of MDM2 protein before treatment . Phase I clinical . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.